Mithramycin and analogs for overcoming cisplatin resistance in ovarian cancer

David Schweer; J. Robert McCorkle; Jurgen Rohr; Oleg V. Tsodikov; Frederick Ueland; Jill Kolesar

doi:10.3390/biomedicines9010070

Mithramycin and analogs for overcoming cisplatin resistance in ovarian cancer

David Schweer, J. Robert McCorkle, Jurgen Rohr, Oleg V. Tsodikov, Frederick Ueland, Jill Kolesar

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Ovarian cancer is a highly deadly malignancy in which recurrence is considered incurable. Resistance to platinum-based chemotherapy bodes a particularly abysmal prognosis, underscoring the need for novel therapeutic agents and strategies. The use of mithramycin, an antineoplastic antibiotic, has been previously limited by its narrow therapeutic window. Recent advances in semisynthetic methods have led to mithramycin analogs with improved pharmacological profiles. Mithramycin inhibits the activity of the transcription factor Sp1, which is closely linked with ovarian tumorigenesis and platinum-resistance. This article summarizes recent clinical developments related to mithramycin and postulates a role for the use of mithramycin, or its analog, in the treatment of platinum-resistant ovarian cancer.

Original language	English
Article number	70
Pages (from-to)	1-11
Number of pages	11
Journal	Biomedicines
Volume	9
Issue number	1
DOIs	https://doi.org/10.3390/biomedicines9010070
State	Published - Jan 1 2021

Bibliographical note

Funding Information:
Funding: This research was funded by a NIH Training Grant, T32CA160003, the 2020 Inter-Departmental Collaboration (IDC) Award from the University of Kentucky College of Pharmacy, and by the University of Kentucky Markey Cancer Center (P30 CA177558)

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

Mithramycin
Novel therapeutics
Ovarian cancer
Platinum-resistant
Sp1

ASJC Scopus subject areas

Medicine (miscellaneous)
Biochemistry, Genetics and Molecular Biology (all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/biomedicines9010070

Cite this

@article{27c9f22f5dfe41eca06d7cbaca36845a,

title = "Mithramycin and analogs for overcoming cisplatin resistance in ovarian cancer",

abstract = "Ovarian cancer is a highly deadly malignancy in which recurrence is considered incurable. Resistance to platinum-based chemotherapy bodes a particularly abysmal prognosis, underscoring the need for novel therapeutic agents and strategies. The use of mithramycin, an antineoplastic antibiotic, has been previously limited by its narrow therapeutic window. Recent advances in semisynthetic methods have led to mithramycin analogs with improved pharmacological profiles. Mithramycin inhibits the activity of the transcription factor Sp1, which is closely linked with ovarian tumorigenesis and platinum-resistance. This article summarizes recent clinical developments related to mithramycin and postulates a role for the use of mithramycin, or its analog, in the treatment of platinum-resistant ovarian cancer.",

keywords = "Mithramycin, Novel therapeutics, Ovarian cancer, Platinum-resistant, Sp1",

author = "David Schweer and McCorkle, {J. Robert} and Jurgen Rohr and Tsodikov, {Oleg V.} and Frederick Ueland and Jill Kolesar",

note = "Funding Information: Funding: This research was funded by a NIH Training Grant, T32CA160003, the 2020 Inter-Departmental Collaboration (IDC) Award from the University of Kentucky College of Pharmacy, and by the University of Kentucky Markey Cancer Center (P30 CA177558) Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = jan,

day = "1",

doi = "10.3390/biomedicines9010070",

language = "English",

volume = "9",

pages = "1--11",

number = "1",

}

TY - JOUR

T1 - Mithramycin and analogs for overcoming cisplatin resistance in ovarian cancer

AU - Schweer, David

AU - McCorkle, J. Robert

AU - Rohr, Jurgen

AU - Tsodikov, Oleg V.

AU - Ueland, Frederick

AU - Kolesar, Jill

N1 - Funding Information: Funding: This research was funded by a NIH Training Grant, T32CA160003, the 2020 Inter-Departmental Collaboration (IDC) Award from the University of Kentucky College of Pharmacy, and by the University of Kentucky Markey Cancer Center (P30 CA177558) Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Ovarian cancer is a highly deadly malignancy in which recurrence is considered incurable. Resistance to platinum-based chemotherapy bodes a particularly abysmal prognosis, underscoring the need for novel therapeutic agents and strategies. The use of mithramycin, an antineoplastic antibiotic, has been previously limited by its narrow therapeutic window. Recent advances in semisynthetic methods have led to mithramycin analogs with improved pharmacological profiles. Mithramycin inhibits the activity of the transcription factor Sp1, which is closely linked with ovarian tumorigenesis and platinum-resistance. This article summarizes recent clinical developments related to mithramycin and postulates a role for the use of mithramycin, or its analog, in the treatment of platinum-resistant ovarian cancer.

AB - Ovarian cancer is a highly deadly malignancy in which recurrence is considered incurable. Resistance to platinum-based chemotherapy bodes a particularly abysmal prognosis, underscoring the need for novel therapeutic agents and strategies. The use of mithramycin, an antineoplastic antibiotic, has been previously limited by its narrow therapeutic window. Recent advances in semisynthetic methods have led to mithramycin analogs with improved pharmacological profiles. Mithramycin inhibits the activity of the transcription factor Sp1, which is closely linked with ovarian tumorigenesis and platinum-resistance. This article summarizes recent clinical developments related to mithramycin and postulates a role for the use of mithramycin, or its analog, in the treatment of platinum-resistant ovarian cancer.

KW - Mithramycin

KW - Novel therapeutics

KW - Ovarian cancer

KW - Platinum-resistant

KW - Sp1

UR - http://www.scopus.com/inward/record.url?scp=85099828976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85099828976&partnerID=8YFLogxK

U2 - 10.3390/biomedicines9010070

DO - 10.3390/biomedicines9010070

M3 - Review article

AN - SCOPUS:85099828976

VL - 9

SP - 1

EP - 11

JO - Biomedicines

JF - Biomedicines

IS - 1

M1 - 70

ER -

Mithramycin and analogs for overcoming cisplatin resistance in ovarian cancer

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this